WO2008022755A1 - Elastomeric toroidal ring for blood expression - Google Patents
Elastomeric toroidal ring for blood expression Download PDFInfo
- Publication number
- WO2008022755A1 WO2008022755A1 PCT/EP2007/007317 EP2007007317W WO2008022755A1 WO 2008022755 A1 WO2008022755 A1 WO 2008022755A1 EP 2007007317 W EP2007007317 W EP 2007007317W WO 2008022755 A1 WO2008022755 A1 WO 2008022755A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression
- skin
- ring
- cap
- incision
- Prior art date
Links
- 239000008280 blood Substances 0.000 title description 21
- 210000004369 blood Anatomy 0.000 title description 21
- 210000001124 body fluid Anatomy 0.000 claims abstract description 14
- 239000010839 body fluid Substances 0.000 claims abstract description 12
- 239000013536 elastomeric material Substances 0.000 claims abstract description 8
- 238000012360 testing method Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000003825 pressing Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 description 14
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000000463 material Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15101—Details
- A61B5/15115—Driving means for propelling the piercing element to pierce the skin, e.g. comprising mechanisms based on shape memory alloys, magnetism, solenoids, piezoelectric effect, biased elements, resilient elements, vacuum or compressed fluids
- A61B5/15117—Driving means for propelling the piercing element to pierce the skin, e.g. comprising mechanisms based on shape memory alloys, magnetism, solenoids, piezoelectric effect, biased elements, resilient elements, vacuum or compressed fluids comprising biased elements, resilient elements or a spring, e.g. a helical spring, leaf spring, or elastic strap
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150061—Means for enhancing collection
- A61B5/150068—Means for enhancing collection by tissue compression, e.g. with specially designed surface of device contacting the skin area to be pierced
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150412—Pointed piercing elements, e.g. needles, lancets for piercing the skin
- A61B5/150419—Pointed piercing elements, e.g. needles, lancets for piercing the skin comprising means for capillary action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150412—Pointed piercing elements, e.g. needles, lancets for piercing the skin
- A61B5/150435—Specific design of proximal end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150503—Single-ended needles
- A61B5/150511—Details of construction of shaft
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15101—Details
- A61B5/15103—Piercing procedure
- A61B5/15107—Piercing being assisted by a triggering mechanism
Definitions
- the present invention generally relates to an expression device and more specifically, but not exclusively, concerns an elastomeric toroidal ring for expressing body fluid from an incision.
- the acquisition and testing of bodily fluids is useful for many purposes and continues to grow in importance for use in medical diagnosis and treatment, such as for diabetes, and in other diverse applications.
- medical diagnosis and treatment such as for diabetes, and in other diverse applications.
- Testing can be performed on various bodily fluids and, for certain applications, is particularly related to the testing of blood and/or interstitial fluid. Performing home diagnostics can sometimes be a painful experience.
- the incision site is pressed against an expression member, or vice versa, in order to locally increase the blood pressure inside the capillary channels that feed blood to the incision, thereby increasing bleeding from the incision.
- the results from this pressing technique are sometimes inconsistent, such that an insufficient sample for testing purposes is bled from the incision.
- the fluid sample is insufficient, the patient then has to re-lance another site and continue the process again, which can be quite painful. Therefore, it is desirable to have an expression device that is able to consistently provide a sufficient fluid sample for testing purposes.
- the expression device includes an expressing cap that defines a lancet opening.
- the expression cap has a skin contacting surface that is generally flat and positioned to face tissue during expression of body fluid.
- the expression cap includes an elastomeric ring extending around the lancet opening from the skin contacting surface.
- the elastomeric ring includes elastomeric material.
- the expression cap has a beveled surface between the lancet opening and the elastomeric ring to enhance expression of the body fluid when the expression cap is pressed around an incision site.
- Another aspect concerns a method for expressing fluid.
- an incision is formed in skin.
- Body fluid is expressed from the incision by pressing around the incision in the skin an expression cap that includes an elastomeric ring made from elastomeric material and a beveled surface located inside the elastomeric ring.
- FIG. 1 is a top plan view of an expression device according to one embodiment.
- FIG. 2 is a side perspective view of the FIG. 1 expression device.
- FIG. 3 is a second top plan view of the FIG. 1 expression device that identifies the various dimensions in the device.
- FIG. 4 is a side view of a variation of the FIG. 1 expression device that includes an over- mold layer.
- FIG. 5 is a cross-sectional view of the FIG. 1 expression device.
- the present invention generally concerns an expression device for expressing fluid from an incision.
- the expression device includes an elastomeric ring, such as an o-ring, that is mounted to an expression plate, hi one form, the expression device can have a unitary structure, and in another form, the device can have a two-component, complementary structure, such as an o-ring mounted to a support body.
- the expression device can be fabricated from a single material, such as silicone or other types of flexible elastomeric plastics, or a hard plastic, like polystyrene or ABS.
- the expression device can be fabricated from two or more materials.
- the o-ring can be fabricated from an elastomeric material, and the support can be fabricated from a hard plastic with an elastomeric overmold.
- the o-ring can be made of hard plastic, and the support can be made from an elastomeric plastic, hi one particular embodiment, the o-ring has an internal diameter of 7 mm and a cross-sectional width of 1.5 mm.
- the support in this embodiment defines a lancet opening that has an internal diameter of 6 mm.
- the support has a countersink or beveled surface around the lancet opening.
- the countersink can have an angle of 20° to 30°.
- FIG. 1 illustrates an expression device 30 according to one embodiment, among many, of the present invention.
- the expression device 30 includes an expression cap 32 that is coupled to an expression body or plate 34.
- the expression cap 32 can be installed on other devices.
- the expression cap 32 can be installed on a lancing device or on an integrated device, to name a few.
- various features of the expression device can be adapted for other systems. Nonlimiting examples of some systems in which the expression device 30 can be adapted for use are illustrated and described in the following: U.S. Patent No. 5,879,311 to Duchon et al., issued March 9, 1999;
- the expression cap 32 includes a base 36 and an expression ring 38.
- the base 36 has a flange 40 upon which the expression ring 38 rests.
- the flange 40 extends from a collar 42.
- the collar 42 is configured to be received in a plate opening 44 in the expression plate 34 (FIG. 1). It should be appreciated, however, that the collar 42 can be received into other devices, such as lancing devices.
- the expression cap 32 is generally ring shaped and defines an expression or lancet opening 46 through which a piercing device, such as a lancet or needle, extends during lancing and where a fluid sample is collected.
- a piercing device such as a lancet or needle
- the expression device 30 in one form can have a unitary structure in which the expression cap 32 and the expression plate 34 are formed as a single structure.
- the expression device 30 can have two or more components in a complementary structure.
- the expression ring 38 is in the form of an o-ring attached to the expression flange 40.
- the expression device 30 can be fabricated from a single material, such as silicone or other elastomeric plastics, or a hard plastic, such as polystyrene or ABS.
- the expression device 30 can be fabricated from one or more materials.
- the o-ring can be fabricated from elastomeric material and the expression cap 32 can be fabricated from a hard plastic. It should be recognized that other types of material combinations can be used in other embodiments.
- the expression ring 38 has an outer contact surface 48 that is generally curved and configured to contact the skin during expression.
- the expression cap 32 has a beveled or countersink surface 50 that surrounds the expression opening 46. As will be explained below, it was discovered that a 20° angle for the beveled surface 50 provided unexpected, exceptional results when expressing fluid from an incision.
- the beveled surface 50 is disposed on the expression cap 32, but it is contemplated that the beveled surface 50 can be located on other components.
- the beveled surface 50 is located on the expression ring 38.
- the expression ring 38 is in the form of a toroidal (doughnut shaped) ring, such as an o-ring, but it is envisioned that the expression ring 38 can be shaped differently in other embodiments.
- FIG. 3 provides a second top plan view of the expression device 30 in order to illustrate the various dimensions of the expression device 30.
- the dimensions illustrated in FIG. 3 include an outer diameter 52, an inner diameter 54, and a cross-sectional width 56 of the expression ring 38.
- FIG. 3 illustrates an outer diameter 58 of the expression opening 46.
- the outer diameter 52 of the expression ring 38 is 10 mm
- the inner diameter 54 of expression ring 38 is 7 mm. Consequently, the cross-sectional width 56 of the expression ring 38 is 1.5 mm.
- the internal diameter 58 of the expression opening 46 is 6 mm. It is envisioned that in other embodiments one or more of these dimensions can vary. Moreover, it should be recognized that, due to manufacturing tolerances, these dimensions can vary within a specified range.
- FIG. 4 illustrates a variation in which an overmold layer 60 of elastomeric material is deposited over the expression ring 38 as well as the face of the expression cap 32.
- the overmold layer 60 helps in expressing fluid from the incision.
- the overmold layer 60 is made from rubber, but it is envisioned that in other embodiments, the overmold layer 60 can be made from other materials.
- the overmold layer 60 is optional.
- the flange 40 of the expression cap 32 has a generally flat skin contacting surface or face 62 upon which the expression ring 38 is disposed. During expression of fluid from the incision, the skin contacting surface 62 faces the skin or other tissue in a generally parallel manner.
- the expression ring 38 has a height 64 that the expression ring 38 extends from the skin contacting surface 62.
- the height 64 of the expression ring 38 relative to the skin contacting surface 62 is approximately 0.5 mm. However, in other embodiments, this height 64 might vary.
- the expression cap 32 has the beveled skin contacting surface 50 located between the expression ring 38 and the expression opening 46.
- the beveled surface 50 forms a concave depression 65 around the expression opening 46.
- the beveled surface 50 has a countersink angle 66.
- the countersink angle 66 is between 20° to 30°. Unexpectedly, it was discovered that the countersink angle 66 of 20° provided exceptional results for expressing fluid.
- Table I has been provided below which shows the results of a control study.
- microsampler 68 In the study protocol, three healthy subjects with normal skin types were lanced with a conventional microsampler 68 of a type commonly known in the art.
- the lancet of the microsampler 68 lanced an incision in the skin with a single forward and backward movement through the expression or lancet opening 46.
- the microsampler 68 was fired using a conventional spring-based lancing mechanism, but it should be recognized that other types of lancing or firing mechanisms can be used to fire the lancet.
- Each subject was lanced to a depth of 1.8 mm on both hands as well as on the forearm and the radial side of the ring, middle, and index fingers.
- the subject Prior to lancing the skin, the subject pushed the incision site against one of three types of expression rings: a control type, an o-ring type, and a concave type. Fifteen (15) tests (N) were performed for each type of expression ring.
- the control type expression member was generally rigid and ring-shaped, and the surface that contacts the skin in the control was generally flat.
- the o-ring type expression ring With the o-ring type expression ring, the ring had an elastic o-ring that was pressed against the skin, but the o-ring type expression ring did not have a beveled surface around the expression opening.
- the concave type expression ring was configured in the manner as described above. That is, the concave expression ring included the expression cap 32 of the type illustrated in FIGS. 1 and 5.
- the expression cap 32 that was tested had a beveled surface 50 with a countersink angle 66 of 20°, and the expression cap 32 had the same dimensions as discussed above.
- the "Lancing Success Rate” column in Table I lancing was considered successful when the sample volume of blood produced on the skin was at least 0.1 ⁇ L, regardless of the manner in which the sample volume was obtained.
- the "Lancing Success Rate” column in Table I reflects whether the incision was capable of ever producing a sufficient fluid sample. For example, if the microsampler did not cut enough capillaries beneath the skin to produce a sufficient sample size, then the lancing would have been considered a failure. Lancing success could have been achieved with or without the need for expressing fluid. So if the incision by itself bled a sufficient volume of blood, without any type of expression, the lancing would have been considered successful.
- Rate columns occurred when the particular expression ring could not express a sufficient amount of blood, but a sufficient amount (i.e., > 0.1 ⁇ L) was able to be expressed in some other manner, such as by squeezing the skin.
- a sufficient amount i.e., > 0.1 ⁇ L
- the expression cap 32 with countersink angle 66 of 20° was able to successfully express fluid every time, whereas the control and o-ring expression ring types were considerably less successful.
- the expression cap 32 with countersink angle 66 of 20° was able to produce over twice as much blood as compared to the control and o-ring expression ring types.
- the "Percent (%) Improvement (Expressed Blood) Over Control” column shows the percentage difference in volume between the expression ring being tested and the control. Looking at Table I, with the expression cap 32 having a countersink angle 66 of 20°, the percent improvement over the control expression ring was significant, specifically 148.1%. Even when this concave ring type is compared with the o-ring type expression ring, the concave ring type with a 20° countersink angle 66 represented about a 107.9 % improvement in mean blood volume expressed. Thus, it should be appreciated that the concave expression ring enhances the ability to consistently provide a sufficient fluid sample for testing purposes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
An expression device includes an expressing cap that defines a lancet opening. The expression cap has a skin contacting surface that is generally flat and positioned to face tissue during expression of body fluid. The expression cap includes an elastomeric ring extending around the lancet opening from the skin contacting surface. The elastomeric ring is made from elastomeric material. The expression cap has a beveled surface between the lancet opening and the elastomeric ring to enhance expression of the body fluid when the expression cap is pressed around an incision site. It was discovered that when the beveled was angled at about 20°, expression of the body fluid was significantly enhanced.
Description
ELASTOMERIC TOROIDAL RING FOR BLOOD EXPRESSION
BACKGROUND The present invention generally relates to an expression device and more specifically, but not exclusively, concerns an elastomeric toroidal ring for expressing body fluid from an incision. The acquisition and testing of bodily fluids is useful for many purposes and continues to grow in importance for use in medical diagnosis and treatment, such as for diabetes, and in other diverse applications. In the medical field, it is desirable for lay operators to perform tests routinely, quickly, and reproducibly outside of a laboratory setting, with rapid results and a readout of the resulting test information. Testing can be performed on various bodily fluids and, for certain applications, is particularly related to the testing of blood and/or interstitial fluid. Performing home diagnostics can sometimes be a painful experience. While certain locations on the body provide ample blood supplies, such as the lingers, these locations tend to have high nerve densities, which in turn can sometimes make lancing to collect the sample a very painful experience. Alternate body sites, such as the forearm and legs, have lower nerve densities, and thus the patient experiences less pain when lancing those sites. However, alternate sites also typically supply less blood than the fingers. Having deeper penetration depths when lancing alternate sites can sometimes increase the blood flow from the incision. However, lancing at too great of depths tends to be more painful. Therefore, it is desirable to minimize the pain associated with lancing the skin for home diagnostic testing. The minimal sample volumes needed for accurate testing have reduced over the years to the point where less than 1 μL samples volumes are common. However, most alternate sites still do not reliably produce sufficient quantities of blood to ensure consistently accurate results with minimal pain. Similarly, shallow incisions on the fingers, which tend to minimize pain, still do not reliably bleed sufficient volumes of blood for consistent test results.
Various design solutions have been proposed to increase or enhance the bleeding from incisions. In one technique, the incision site is pressed against an expression member, or vice versa, in order to locally increase the blood pressure inside the capillary channels that feed blood to the incision, thereby increasing bleeding from the incision. The results from this pressing technique are sometimes inconsistent, such that an insufficient sample for testing purposes is
bled from the incision. When the fluid sample is insufficient, the patient then has to re-lance another site and continue the process again, which can be quite painful. Therefore, it is desirable to have an expression device that is able to consistently provide a sufficient fluid sample for testing purposes.
Thus, needs remain for further contributions in this area of technology.
SUMMARY
One aspect concerns an expression device. The expression device includes an expressing cap that defines a lancet opening. The expression cap has a skin contacting surface that is generally flat and positioned to face tissue during expression of body fluid. The expression cap includes an elastomeric ring extending around the lancet opening from the skin contacting surface. The elastomeric ring includes elastomeric material. The expression cap has a beveled surface between the lancet opening and the elastomeric ring to enhance expression of the body fluid when the expression cap is pressed around an incision site.
Another aspect concerns a method for expressing fluid. With the method, an incision is formed in skin. Body fluid is expressed from the incision by pressing around the incision in the skin an expression cap that includes an elastomeric ring made from elastomeric material and a beveled surface located inside the elastomeric ring.
Further forms, objects, features, aspects, benefits, advantages, and embodiments of the present invention will become apparent from a detailed description and drawings provided herewith.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a top plan view of an expression device according to one embodiment.
FIG. 2 is a side perspective view of the FIG. 1 expression device.
FIG. 3 is a second top plan view of the FIG. 1 expression device that identifies the various dimensions in the device.
FIG. 4 is a side view of a variation of the FIG. 1 expression device that includes an over- mold layer.
FIG. 5 is a cross-sectional view of the FIG. 1 expression device.
DESCRIPTION OF THE SELECTED EMBODIMENTS
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiments illustrated in the drawings and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated device, and such further applications of the principles of the invention as illustrated therein being contemplated as would normally occur to one skilled in the art to which the invention relates. A number of embodiments of the invention are shown in detail; although it will be apparent to those skilled in the relevant art that some features that are not relevant to the present invention may not be shown for the sake of clarity. It should be noted that directional terms, such as "up", "down", "top" and "bottom", are used herein solely for the convenience of the reader in order to aid in the reader's understanding of the illustrated embodiments, and it is not the intent that the use of these directional terms in any manner limit the described, illustrated, and/or claimed features to a specific direction or orientation. The present invention generally concerns an expression device for expressing fluid from an incision. The expression device includes an elastomeric ring, such as an o-ring, that is mounted to an expression plate, hi one form, the expression device can have a unitary structure, and in another form, the device can have a two-component, complementary structure, such as an o-ring mounted to a support body. For the single molded piece, the expression device can be fabricated from a single material, such as silicone or other types of flexible elastomeric plastics, or a hard plastic, like polystyrene or ABS. For the two-component form, the expression device can be fabricated from two or more materials. For instance, the o-ring can be fabricated from an elastomeric material, and the support can be fabricated from a hard plastic with an elastomeric overmold. In another embodiment, the o-ring can be made of hard plastic, and the support can be made from an elastomeric plastic, hi one particular embodiment, the o-ring has an internal diameter of 7 mm and a cross-sectional width of 1.5 mm. The support in this embodiment defines a lancet opening that has an internal diameter of 6 mm. In a further embodiment, the support has a countersink or beveled surface around the lancet opening. The countersink can have an angle of 20° to 30°. For an expression device having a concave expression ring with a
countersink angle of 20°, it was discovered that the expression device unexpectedly improved expression of blood by 148.1% as compared to a control expression device.
FIG. 1 illustrates an expression device 30 according to one embodiment, among many, of the present invention. As can be seen, the expression device 30 includes an expression cap 32 that is coupled to an expression body or plate 34. It should be appreciated that the expression cap 32 can be installed on other devices. For example, the expression cap 32 can be installed on a lancing device or on an integrated device, to name a few. It is also contemplated that various features of the expression device can be adapted for other systems. Nonlimiting examples of some systems in which the expression device 30 can be adapted for use are illustrated and described in the following: U.S. Patent No. 5,879,311 to Duchon et al., issued March 9, 1999;
U.S. Published Application No. 2004/0127818 Al to Roe et al., published July 1, 2004; U.S. Published Application No. 2003/0050573 Al to Kuhr et al., published March 13, 2003; and U.S. Published Application No. 2003/0018282 Al to Effenhauser et al., published January 23, 2003, which are hereby incorporated by reference. Turning to FIG. 2, the expression cap 32 includes a base 36 and an expression ring 38.
The base 36 has a flange 40 upon which the expression ring 38 rests. The flange 40 extends from a collar 42. The collar 42 is configured to be received in a plate opening 44 in the expression plate 34 (FIG. 1). It should be appreciated, however, that the collar 42 can be received into other devices, such as lancing devices. Referring again to FIG. 1, the expression cap 32 is generally ring shaped and defines an expression or lancet opening 46 through which a piercing device, such as a lancet or needle, extends during lancing and where a fluid sample is collected. Although the expression cap and its various components are ring shaped, it is contemplated that the expression cap and its components can have a different overall shape in other embodiments. As mentioned previously, the expression device 30 in one form can have a unitary structure in which the expression cap 32 and the expression plate 34 are formed as a single structure. In other embodiments, the expression device 30 can have two or more components in a complementary structure. In the illustrated embodiment, the expression ring 38 is in the form of an o-ring attached to the expression flange 40. For a single molded unitary embodiment, the expression device 30 can be fabricated from a single material, such as silicone or other elastomeric plastics, or a hard plastic, such as polystyrene or ABS. When in a multi-
component form, the expression device 30 can be fabricated from one or more materials. For example, in one embodiment, the o-ring can be fabricated from elastomeric material and the expression cap 32 can be fabricated from a hard plastic. It should be recognized that other types of material combinations can be used in other embodiments. Referring again to FIG. 1, the expression ring 38 has an outer contact surface 48 that is generally curved and configured to contact the skin during expression. Inside the expression ring 38, the expression cap 32 has a beveled or countersink surface 50 that surrounds the expression opening 46. As will be explained below, it was discovered that a 20° angle for the beveled surface 50 provided unexpected, exceptional results when expressing fluid from an incision. In the illustrated embodiment, the beveled surface 50 is disposed on the expression cap 32, but it is contemplated that the beveled surface 50 can be located on other components. For instance, in another variation, the beveled surface 50 is located on the expression ring 38. In the illustrated embodiment, the expression ring 38 is in the form of a toroidal (doughnut shaped) ring, such as an o-ring, but it is envisioned that the expression ring 38 can be shaped differently in other embodiments.
FIG. 3 provides a second top plan view of the expression device 30 in order to illustrate the various dimensions of the expression device 30. The dimensions illustrated in FIG. 3 include an outer diameter 52, an inner diameter 54, and a cross-sectional width 56 of the expression ring 38. In addition, FIG. 3 illustrates an outer diameter 58 of the expression opening 46. In one embodiment, the outer diameter 52 of the expression ring 38 is 10 mm, and the inner diameter 54 of expression ring 38 is 7 mm. Consequently, the cross-sectional width 56 of the expression ring 38 is 1.5 mm. In this embodiment, the internal diameter 58 of the expression opening 46 is 6 mm. It is envisioned that in other embodiments one or more of these dimensions can vary. Moreover, it should be recognized that, due to manufacturing tolerances, these dimensions can vary within a specified range.
FIG. 4 illustrates a variation in which an overmold layer 60 of elastomeric material is deposited over the expression ring 38 as well as the face of the expression cap 32. The overmold layer 60 helps in expressing fluid from the incision. In one particular form, the overmold layer 60 is made from rubber, but it is envisioned that in other embodiments, the overmold layer 60 can be made from other materials. As should be appreciated from above, in other embodiments,
the overmold layer 60 is optional. With continued reference to FIG. 4, the flange 40 of the expression cap 32 has a generally flat skin contacting surface or face 62 upon which the expression ring 38 is disposed. During expression of fluid from the incision, the skin contacting surface 62 faces the skin or other tissue in a generally parallel manner. Relative to the skin contacting surface 62, the expression ring 38 has a height 64 that the expression ring 38 extends from the skin contacting surface 62. In one embodiment, the height 64 of the expression ring 38 relative to the skin contacting surface 62 is approximately 0.5 mm. However, in other embodiments, this height 64 might vary.
As can be seen in FIG. 5, the expression cap 32 has the beveled skin contacting surface 50 located between the expression ring 38 and the expression opening 46. The beveled surface 50 forms a concave depression 65 around the expression opening 46. Relative to the skin contacting surface 62, the beveled surface 50 has a countersink angle 66. In one form, the countersink angle 66 is between 20° to 30°. Unexpectedly, it was discovered that the countersink angle 66 of 20° provided exceptional results for expressing fluid.
Table I has been provided below which shows the results of a control study.
Table I
* Lancing success is defined as > 0.1 μL blood on the skin surface with or without (manual expression by finger squeeze) an expression ring
** Expression success rate is defined as > 0.1 μL blood to the skin surface with the expression ring
In the study protocol, three healthy subjects with normal skin types were lanced with a conventional microsampler 68 of a type commonly known in the art. The microsampler 68 used
in the control study included a generally flat lancet with a capillary groove for transporting fluid to a test strip or sensor attached to the lancet. The lancet of the microsampler 68 lanced an incision in the skin with a single forward and backward movement through the expression or lancet opening 46. The microsampler 68 was fired using a conventional spring-based lancing mechanism, but it should be recognized that other types of lancing or firing mechanisms can be used to fire the lancet. Each subject was lanced to a depth of 1.8 mm on both hands as well as on the forearm and the radial side of the ring, middle, and index fingers.
Prior to lancing the skin, the subject pushed the incision site against one of three types of expression rings: a control type, an o-ring type, and a concave type. Fifteen (15) tests (N) were performed for each type of expression ring. The control type expression member was generally rigid and ring-shaped, and the surface that contacts the skin in the control was generally flat. With the o-ring type expression ring, the ring had an elastic o-ring that was pressed against the skin, but the o-ring type expression ring did not have a beveled surface around the expression opening. On the other hand, the concave type expression ring was configured in the manner as described above. That is, the concave expression ring included the expression cap 32 of the type illustrated in FIGS. 1 and 5. The expression cap 32 that was tested had a beveled surface 50 with a countersink angle 66 of 20°, and the expression cap 32 had the same dimensions as discussed above.
After lancing, the incision site was firmly held against each type of expression ring for 4 seconds. The finger was removed and blood on the surface of the skin was collected with a capillary tube. The volume of blood in the capillary tube was then measured. The results from the tests of the three expression ring types have been tabulated in Table I.
For the "Lancing Success Rate" column in Table I, lancing was considered successful when the sample volume of blood produced on the skin was at least 0.1 μL, regardless of the manner in which the sample volume was obtained. In other words, the "Lancing Success Rate" column in Table I reflects whether the incision was capable of ever producing a sufficient fluid sample. For example, if the microsampler did not cut enough capillaries beneath the skin to produce a sufficient sample size, then the lancing would have been considered a failure. Lancing success could have been achieved with or without the need for expressing fluid. So if the incision by itself bled a sufficient volume of blood, without any type of expression, the lancing
would have been considered successful. Likewise, even if use of the expression ring was unable to produce a sufficient sample volume, but a sample volume > 0.1 μL was afterwards created by expressing in some other manner, such as by pinching or squeezing the skin, then lancing was considered successful. The 0.1 μL cutoff value was selected because 0.1 μL sample volume sizes are typically the lower limit for accurate home diagnostic testing in the current state of the art. The "Mean Blood Volume Expressed" column in Table I indicates the mean blood volume collected over all of the test for a particular expression ring type. Regarding the "Expression Success Rate" column in Table I, expression with a selected expression ring type was considered successful when the sample volume of blood on the skin surface was > 0.1 μL. It should be recognized that the differences between the "Lancing Success Rate" and "Expression Success
Rate" columns occurred when the particular expression ring could not express a sufficient amount of blood, but a sufficient amount (i.e., > 0.1 μL) was able to be expressed in some other manner, such as by squeezing the skin. As can be seen in Table I, the expression cap 32 with countersink angle 66 of 20° (concave ring type) was able to successfully express fluid every time, whereas the control and o-ring expression ring types were considerably less successful.
Unexpectedly, it was discovered that the expression cap 32 with countersink angle 66 of 20° was able to produce over twice as much blood as compared to the control and o-ring expression ring types. The "Percent (%) Improvement (Expressed Blood) Over Control" column shows the percentage difference in volume between the expression ring being tested and the control. Looking at Table I, with the expression cap 32 having a countersink angle 66 of 20°, the percent improvement over the control expression ring was significant, specifically 148.1%. Even when this concave ring type is compared with the o-ring type expression ring, the concave ring type with a 20° countersink angle 66 represented about a 107.9 % improvement in mean blood volume expressed. Thus, it should be appreciated that the concave expression ring enhances the ability to consistently provide a sufficient fluid sample for testing purposes.
While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiment has been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected. All publications, patents and patent applications cited in this specification are herein
incorporated by reference as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference as set forth in its entirety herein.
Claims
1. An expression device, comprising: an expressing cap defining a lancet opening; the expression cap having a skin contacting surface that is generally flat and positioned to face tissue during expression of body fluid; the expression cap including an elastomeric ring extending around the lancet opening from the skin contacting surface, wherein the elastomeric ring includes elastomeric material; and the expression cap having a beveled surface between the lancet opening and the elastomeric ring to enhance expression of the body fluid when the expression cap is pressed around an incision site.
2. The device of claim 1, wherein the beveled surface extends at a 20° to 30° angle relative to the skin contacting surface.
3. The device of claim 1, wherein the beveled surface extends at a 20° angle relative to the skin contacting surface.
4. The device of claim 2, wherein: the elastomeric ring has a outer diameter of 10 mm; the elastomeric ring has an inner diameter of 7 mm; the elastomeric ring has a height of 1.5 mm relative to the skin contacting surface; and the lancet opening has an internal diameter of 6 mm.
5. The device of claim 1, wherein the elastomeric ring is an o-ring.
6. The device of claim 1, wherein the expression cap is generally ring-shaped.
7. The device of claim 1, further comprising an overmold layer covering the elastomeric ring.
8. A method, comprising: forming an incision in skin; and expressing body fluid from the incision by pressing around the incision in the skin an expression cap that includes an elastomeric ring made from elastomeric material and a beveled surface located inside the elastomeric ring.
9. The method of claim 8, wherein: the expression cap has a generally flat skin contacting surface that extends parallel to the skin when pressed against the skin; the beveled surface extends at a 20° angle relative to the skin contacting surface; and said expressing includes pressing the beveled surface against the skin.
10. The method of claim 9, further comprising: pressing the expression cap against the skin before said forming the incision.
11. The method of claim 9, wherein said expressing includes pressing the expression cap against the skin for at least 4 seconds.
12. The method of claim 9, wherein said forming the incision includes lancing the skin to a depth of 1.8 mm.
13. The method of claim 8, further comprising: wherein the expression cap has a generally flat skin contacting surface that extends parallel to the skin when pressed against the skin; wherein the beveled surface extends at a 20° angle relative to the skin contacting surface; wherein said expressing includes pressing the beveled surface against the skin; pushing the expression cap against the skin before said forming the incision; wherein said expressing includes pressing the expression cap against the skin for at least 4 seconds; and wherein said forming the incision includes lancing the skin to a depth of 1.8 mm.
14. The method of claim 8, wherein: the expression cap has a generally flat skin contacting surface that extends parallel to the skin when pressed against the skin; the beveled surface extends between a 20° to 30° angle relative to the skin contacting surface; and said expressing includes pressing the beveled surface against the skin.
15. The method of claim 8, further comprising testing the body fluid.
16. The method of claim 8, wherein said expressing includes pressing the expression cap against the skin until at least 0.1 μL of the body fluid is on the surface of the skin.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL07801757T PL2056717T3 (en) | 2006-08-22 | 2007-08-18 | Elastomeric toroidal ring for blood expression |
EP07801757A EP2056717B1 (en) | 2006-08-22 | 2007-08-18 | Elastomeric toroidal ring for blood expression |
ES07801757T ES2390368T3 (en) | 2006-08-22 | 2007-08-18 | Elastomeric toroidal ring for blood collection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/466,202 US20080065130A1 (en) | 2006-08-22 | 2006-08-22 | Elastomeric toroidal ring for blood expression |
US11/466,202 | 2006-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008022755A1 true WO2008022755A1 (en) | 2008-02-28 |
Family
ID=38607197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/007317 WO2008022755A1 (en) | 2006-08-22 | 2007-08-18 | Elastomeric toroidal ring for blood expression |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080065130A1 (en) |
EP (1) | EP2056717B1 (en) |
ES (1) | ES2390368T3 (en) |
PL (1) | PL2056717T3 (en) |
WO (1) | WO2008022755A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010049048A1 (en) * | 2008-10-29 | 2010-05-06 | Roche Diagnostics Gmbh | Instrument and system for producing a sample of a body liquid and for analysis thereof |
WO2010087524A3 (en) * | 2009-01-30 | 2010-11-11 | Terumo Kabushiki Kaisha | Injection needle assembly and drug injection device |
AU2011205171B2 (en) * | 2008-10-29 | 2013-10-03 | F. Hoffmann-La Roche Ag | Instrument and system for producing a sample of a body liquid and for analysis thereof |
US9186104B2 (en) | 2007-04-30 | 2015-11-17 | Roche Diabetes Care, Inc. | Instruments and system for producing a sample of a body fluid and for analysis thereof |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
ATE485766T1 (en) | 2001-06-12 | 2010-11-15 | Pelikan Technologies Inc | ELECTRICAL ACTUATING ELEMENT FOR A LANCET |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
CA2448902C (en) | 2001-06-12 | 2010-09-07 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
AU2002348683A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7892185B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
EP2238892A3 (en) | 2003-05-30 | 2011-02-09 | Pelikan Technologies Inc. | Apparatus for body fluid sampling |
DK1633235T3 (en) | 2003-06-06 | 2014-08-18 | Sanofi Aventis Deutschland | Apparatus for sampling body fluid and detecting analyte |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US8282576B2 (en) | 2003-09-29 | 2012-10-09 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for an improved sample capture device |
US9351680B2 (en) | 2003-10-14 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a variable user interface |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
WO2005065414A2 (en) | 2003-12-31 | 2005-07-21 | Pelikan Technologies, Inc. | Method and apparatus for improving fluidic flow and sample capture |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
EP1765194A4 (en) | 2004-06-03 | 2010-09-29 | Pelikan Technologies Inc | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US10646150B2 (en) * | 2013-03-12 | 2020-05-12 | Ascensia Diabetes Care Holdings Ag | Lancing device |
CN111680202B (en) * | 2020-04-24 | 2022-04-26 | 烽火通信科技股份有限公司 | Body-based face image data collection method and device |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306104B1 (en) * | 1996-12-06 | 2001-10-23 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
WO2001089383A2 (en) * | 2000-05-26 | 2001-11-29 | Roche Diagnostics Gmbh | System for removing body fluid, especially blood |
WO2004045375A2 (en) * | 2002-11-15 | 2004-06-03 | Lifescan, Inc. | Cap for a dermal tissue lancing device |
WO2005112763A1 (en) * | 2004-05-21 | 2005-12-01 | F. Hoffmann-La Roche Ag | Device and method for positioning a body part |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5402798A (en) * | 1991-07-18 | 1995-04-04 | Swierczek; Remi | Disposable skin perforator and blood testing device |
JP2572823Y2 (en) * | 1992-02-13 | 1998-05-25 | 株式会社アドバンス | Simple blood sampler |
CA2079192C (en) * | 1992-09-25 | 1995-12-26 | Bernard Strong | Combined lancet and multi-function cap and lancet injector for use therewith |
DE4320463A1 (en) * | 1993-06-21 | 1994-12-22 | Boehringer Mannheim Gmbh | Blood lancet device for drawing blood for diagnostic purposes |
US5582184A (en) * | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5618208A (en) * | 1994-06-03 | 1997-04-08 | Siemens Medical Systems, Inc. | Fully insulated, fully shielded electrical connector arrangement |
US5879311A (en) * | 1996-05-17 | 1999-03-09 | Mercury Diagnostics, Inc. | Body fluid sampling device and methods of use |
US5857983A (en) * | 1996-05-17 | 1999-01-12 | Mercury Diagnostics, Inc. | Methods and apparatus for sampling body fluid |
US6706000B2 (en) * | 1997-11-21 | 2004-03-16 | Amira Medical | Methods and apparatus for expressing body fluid from an incision |
JP4210782B2 (en) * | 1999-10-13 | 2009-01-21 | アークレイ株式会社 | Blood sampling position indicator |
US6706159B2 (en) * | 2000-03-02 | 2004-03-16 | Diabetes Diagnostics | Combined lancet and electrochemical analyte-testing apparatus |
ATE543437T1 (en) * | 2000-06-09 | 2012-02-15 | Diabetes Diagnostics Inc | CAP FOR A LANCET DEVICE |
DE10134650B4 (en) * | 2001-07-20 | 2009-12-03 | Roche Diagnostics Gmbh | System for taking small amounts of body fluid |
DE10142232B4 (en) * | 2001-08-29 | 2021-04-29 | Roche Diabetes Care Gmbh | Process for the production of an analytical aid with a lancet and test element |
US20040127818A1 (en) * | 2002-12-27 | 2004-07-01 | Roe Steven N. | Precision depth control lancing tip |
US20050234489A1 (en) * | 2004-04-16 | 2005-10-20 | John Allen | Method for lancing a dermal tissue target site |
-
2006
- 2006-08-22 US US11/466,202 patent/US20080065130A1/en not_active Abandoned
-
2007
- 2007-08-18 WO PCT/EP2007/007317 patent/WO2008022755A1/en active Application Filing
- 2007-08-18 PL PL07801757T patent/PL2056717T3/en unknown
- 2007-08-18 EP EP07801757A patent/EP2056717B1/en not_active Not-in-force
- 2007-08-18 ES ES07801757T patent/ES2390368T3/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306104B1 (en) * | 1996-12-06 | 2001-10-23 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
WO2001089383A2 (en) * | 2000-05-26 | 2001-11-29 | Roche Diagnostics Gmbh | System for removing body fluid, especially blood |
WO2004045375A2 (en) * | 2002-11-15 | 2004-06-03 | Lifescan, Inc. | Cap for a dermal tissue lancing device |
WO2005112763A1 (en) * | 2004-05-21 | 2005-12-01 | F. Hoffmann-La Roche Ag | Device and method for positioning a body part |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186104B2 (en) | 2007-04-30 | 2015-11-17 | Roche Diabetes Care, Inc. | Instruments and system for producing a sample of a body fluid and for analysis thereof |
WO2010049048A1 (en) * | 2008-10-29 | 2010-05-06 | Roche Diagnostics Gmbh | Instrument and system for producing a sample of a body liquid and for analysis thereof |
EP2548508A1 (en) * | 2008-10-29 | 2013-01-23 | Roche Diagnostics GmbH | Instrument and system for producing a sample of a body liquid and for analysis thereof |
AU2011205171B2 (en) * | 2008-10-29 | 2013-10-03 | F. Hoffmann-La Roche Ag | Instrument and system for producing a sample of a body liquid and for analysis thereof |
WO2010087524A3 (en) * | 2009-01-30 | 2010-11-11 | Terumo Kabushiki Kaisha | Injection needle assembly and drug injection device |
CN102271738A (en) * | 2009-01-30 | 2011-12-07 | 泰尔茂株式会社 | Injection needle assembly and drug injection device |
US8622963B2 (en) | 2009-01-30 | 2014-01-07 | Terumo Kabushiki Kaisha | Injection needle assembly and drug injection device |
US9566393B2 (en) | 2009-01-30 | 2017-02-14 | Terumo Kabushiki Kaisha | Injection needle assembly and drug injection device |
Also Published As
Publication number | Publication date |
---|---|
EP2056717B1 (en) | 2012-07-04 |
EP2056717A1 (en) | 2009-05-13 |
ES2390368T3 (en) | 2012-11-12 |
PL2056717T3 (en) | 2012-12-31 |
US20080065130A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2056717B1 (en) | Elastomeric toroidal ring for blood expression | |
EP1560517B1 (en) | Cap for a dermal tissue lancing device | |
US6645219B2 (en) | Rotatable penetration depth adjusting arrangement | |
EP2293719B1 (en) | Body fluid sampling device -- sampling site interface | |
AU2002247008B2 (en) | Lancet device having capillary action | |
JP2005305158A (en) | Method for lancing dermal tissue target site | |
JP2007136193A (en) | Method for lancing dermal tissue target site using cap with revolving body | |
US20070276425A1 (en) | Painless Blood Sampling Lancet with Bundled Multiple Thin Needles | |
JP3697100B2 (en) | Puncture tool | |
US20040133127A1 (en) | Capillary tube tip design to assist blood flow | |
EP2459068B1 (en) | Lancing device having saddle-shaped tip | |
ZA200701135B (en) | Multiple tip lancet | |
JP2005021291A (en) | Puncture tool | |
CN100415166C (en) | Cap for a dermal tissue lancing device | |
MXPA06008844A (en) | Dampening and retraction mechanism for a lancing device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07801757 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007801757 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |